The observed differences for PSMA expression on tumor cells might be due to a difference in the monoclonal antibodies that had been used in the different studies, heterogeneity of the investigated NSCLC study cohort and/ or differences in interpretation. This evidence concerns the gene FOLH1 and neoplasm.